Rhythm Pharmaceuticals (RYTM) Change in Accured Expenses (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Change in Accured Expenses data on file, last reported at -$5.6 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 54.64% year-over-year to -$5.6 million in Q1 2026; TTM through Mar 2026 was $19.9 million, a 1.9% increase from a year earlier, with the FY2025 full-year figure at $21.9 million, changed 0.12% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$5.6 million, down from $1.3 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for RYTM reached as high as $15.7 million in Q4 2022 and fell as low as -$12.6 million in Q3 2022.
• Historically, Change in Accured Expenses has averaged $3.2 million across 5 years, with a median of $1.3 million in 2025.
• Across the five-year window, Change in Accured Expenses plunged 309.83% in 2022 and jumped 9849.06% in 2023, its largest moves.
• Year by year, Change in Accured Expenses stood at $15.7 million in 2022, then plunged by 69.08% to $4.9 million in 2023, then surged by 212.45% to $15.2 million in 2024, then tumbled by 91.73% to $1.3 million in 2025, then tumbled by 547.65% to -$5.6 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$5.6 million in Q1 2026, $1.3 million in Q4 2025, and $11.0 million in Q3 2025.